Bridging Discoveries and Treatments: The New Landscape of Breast Cancer Research
1. Highlights from This Special Issue
1.1. Application of Deep Learning in Breast Cancer Pathology Image Classification
1.2. The Use of Diffusion-Weighted Imaging (DWI) in Young Breast Cancer Patients
1.3. Association between Non-Alcoholic Fatty Liver Disease (NAFLD) and Triple-Negative Breast Cancer (TNBC)
1.4. Breast Cancer Exposomics
1.5. The Foundational Role of Breast Cancer Cell Lines in Cancer Research
1.6. Progress and Challenges of Immunotherapy Predictive Biomarkers for Triple-Negative Breast Cancer
1.7. Adverse Events of PD-1 or PD-L1 Inhibitors in Triple-Negative Breast Cancer
1.8. In Silico Analysis of Triple-Negative Breast Cancer-Specific Biomarkers
1.9. Neuroendocrine Breast Carcinoma: Characteristics and Prognosis
1.10. Advancements in Post-Mastectomy Breast Reconstruction
1.11. Artificial Intelligence in Breast Cancer Diagnosis: Patient Perspectives
1.12. Investigating the Role of Eosinophils in Reactive Breast Stroma
2. Advancing Frontlines: New Perspectives in Breast Cancer Research
3. Final Reflections
Conflicts of Interest
References
- Qiu, Y.; Dai, Y.; Zhu, L.; Hao, X.; Zhang, L.; Bao, B.; Chen, Y.; Wang, J. Clinicopathological Characteristics and Prognostic Profiles of Breast Carcinoma with Neuroendocrine Features. Life 2023, 13, 532. [Google Scholar] [CrossRef]
- Zhu, J.; Min, N.; Gong, W.; Chen, Y.; Li, X. Identification of Hub Genes and Biological Mechanisms Associated with Non-Alcoholic Fatty Liver Disease and Triple-Negative Breast Cancer. Life 2023, 13, 998. [Google Scholar] [CrossRef] [PubMed]
- Pesapane, F.; Giambersio, E.; Capetti, B.; Monzani, D.; Grasso, R.; Nicosia, L.; Rotili, A.; Sorce, A.; Meneghetti, L.; Carriero, S.; et al. Patients’ Perceptions and Attitudes to the Use of Artificial Intelligence in Breast Cancer Diagnosis: A Narrative Review. Life 2024, 14, 454. [Google Scholar] [CrossRef] [PubMed]
- Yu, J.; Guo, Z.; Wang, L. Progress and Challenges of Immunotherapy Predictive Biomarkers for Triple Negative Breast Cancer in the Era of Single-Cell Multi-Omics. Life 2023, 13, 1189. [Google Scholar] [CrossRef] [PubMed]
- Ashurov, A.; Chelloug, S.A.; Tselykh, A.; Muthanna, M.S.A.; Muthanna, A.; Al-Gaashani, M. Improved Breast Cancer Classification through Combining Transfer Learning and Attention Mechanism. Life 2023, 13, 1945. [Google Scholar] [CrossRef] [PubMed]
- Park, G.E.; Kang, B.J.; Kim, S.H.; Jung, N.Y. The Role of Diffusion-Weighted Imaging Based on Maximum-Intensity Projection in Young Patients with Marked Background Parenchymal Enhancement on Contrast-Enhanced Breast MRI. Life 2023, 13, 1744. [Google Scholar] [CrossRef] [PubMed]
- Neagu, A.N.; Jayaweera, T.; Corrice, L.; Johnson, K.; Darie, C.C. Breast Cancer Exposomics. Life 2024, 14, 402. [Google Scholar] [CrossRef] [PubMed]
- Witt, B.L.; Tollefsbol, T.O. Molecular, Cellular, and Technical Aspects of Breast Cancer Cell Lines as a Foundational Tool in Cancer Research. Life 2023, 13, 2311. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Y.; Wang, J.; Hu, T.; Wang, H.; Long, M.; Liang, B. Adverse Events of PD-1 or PD-L1 Inhibitors in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis. Life 2022, 12, 1990. [Google Scholar] [CrossRef]
- Kaddoura, R.; Alqutami, F.; Asbaita, M.; Hachim, M. In Silico Analysis of Publicly Available Transcriptomic Data for the Identification of Triple-Negative Breast Cancer-Specific Biomarkers. Life 2023, 13, 422. [Google Scholar] [CrossRef]
- Simion, L.; Petrescu, I.; Chitoran, E.; Rotaru, V.; Cirimbei, C.; Ionescu, S.O.; Stefan, D.C.; Luca, D.; Stanculeanu, D.L.; Gheorghe, A.S.; et al. Breast Reconstruction following Mastectomy for Breast Cancer or Prophylactic Mastectomy: Therapeutic Options and Results. Life 2024, 14, 138. [Google Scholar] [CrossRef] [PubMed]
- Schneider, J.; Lim, S.T.; Yi An, Y.; Suh, Y.J. Eosinophilic Dermatoses: Cause of Non-Infectious Erythema after Volume Replacement with Diced Acellular Dermal Matrix in Breast Cancer? Life 2024, 14, 608. [Google Scholar] [CrossRef] [PubMed]
- Onkar, S.S.; Carleton, N.M.; Lucas, P.C.; Bruno, T.C.; Lee, A.V.; Vignali, D.A.A.; Oesterreich, S. The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer Subtypes. Cancer Discov. 2023, 13, 23–40. [Google Scholar] [CrossRef] [PubMed]
- Liu, Y.; Hu, Y.; Xue, J.; Li, J.; Yi, J.; Bu, J.; Zhang, Z.; Qiu, P.; Gu, X. Advances in immunotherapy for triple-negative breast cancer. Mol. Cancer 2023, 22, 145. [Google Scholar] [CrossRef] [PubMed]
- Leon-Ferre, R.A.; Goetz, M.P. Advances in systemic therapies for triple negative breast cancer. BMJ 2023, 381, e071674. [Google Scholar] [CrossRef] [PubMed]
- Tarantino, P.; Corti, C.; Schmid, P.; Cortes, J.; Mittendorf, E.A.; Rugo, H.; Tolaney, S.M.; Bianchini, G.; Andre, F.; Curigliano, G. Immunotherapy for early triple negative breast cancer: Research agenda for the next decade. NPJ Breast Cancer 2022, 8, 23. [Google Scholar] [CrossRef] [PubMed]
- Schmid, P.; Cortes, J.; Dent, R.; Pusztai, L.; McArthur, H.; Kummel, S.; Bergh, J.; Denkert, C.; Park, Y.H.; Hui, R.; et al. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N. Engl. J. Med. 2022, 386, 556–567. [Google Scholar] [CrossRef] [PubMed]
- Marra, A.; Chandarlapaty, S.; Modi, S. Management of patients with advanced-stage HER2-positive breast cancer: Current evidence and future perspectives. Nat. Rev. Clin. Oncol. 2024, 21, 185–202. [Google Scholar] [CrossRef]
- Hurvitz, S.A.; Hegg, R.; Chung, W.P.; Im, S.A.; Jacot, W.; Ganju, V.; Chiu, J.W.Y.; Xu, B.; Hamilton, E.; Madhusudan, S.; et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet 2023, 401, 105–117. [Google Scholar] [CrossRef]
- Squifflet, P.; Saad, E.D.; Loibl, S.; van Mackelenbergh, M.T.; Untch, M.; Rastogi, P.; Gianni, L.; Schneeweiss, A.; Conte, P.; Piccart, M.; et al. Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy. J. Clin. Oncol. 2023, 41, 2988–2997. [Google Scholar] [CrossRef]
- Coles, C.E.; Haviland, J.S.; Kirby, A.M.; Griffin, C.L.; Sydenham, M.A.; Titley, J.C.; Bhattacharya, I.; Brunt, A.M.; Chan, H.Y.C.; Donovan, E.M.; et al. Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): A multicentre, phase 3, non-inferiority, open-label, randomised controlled trial. Lancet 2023, 401, 2124–2137. [Google Scholar] [CrossRef] [PubMed]
- Meattini, I.; Becherini, C.; Caini, S.; Coles, C.E.; Cortes, J.; Curigliano, G.; de Azambuja, E.; Isacke, C.M.; Harbeck, N.; Kaidar-Person, O.; et al. International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations. Lancet Oncol. 2024, 25, e73–e83. [Google Scholar] [CrossRef] [PubMed]
- Demircan, N.V.; Bese, N. New Approaches in Breast Cancer Radiotherapy. Eur. J. Breast Health 2024, 20, 1–7. [Google Scholar] [CrossRef] [PubMed]
- Sigurdson, S.; Thibodeau, S.; Korzeniowski, M.; Moraes, F.Y. A Precise Approach for Radiotherapy of Breast Cancer. Cancer Treat. Res. 2023, 188, 175–198. [Google Scholar] [CrossRef]
- Coles, C.E.; Earl, H.; Anderson, B.O.; Barrios, C.H.; Bienz, M.; Bliss, J.M.; Cameron, D.A.; Cardoso, F.; Cui, W.; Francis, P.A.; et al. The Lancet Breast Cancer Commission. Lancet 2024, 403, 1895–1950. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Hu, T.; Wang, L.; Autelli, R.; Long, M. Bridging Discoveries and Treatments: The New Landscape of Breast Cancer Research. Life 2024, 14, 747. https://doi.org/10.3390/life14060747
Hu T, Wang L, Autelli R, Long M. Bridging Discoveries and Treatments: The New Landscape of Breast Cancer Research. Life. 2024; 14(6):747. https://doi.org/10.3390/life14060747
Chicago/Turabian StyleHu, Taobo, Lei Wang, Riccardo Autelli, and Mengping Long. 2024. "Bridging Discoveries and Treatments: The New Landscape of Breast Cancer Research" Life 14, no. 6: 747. https://doi.org/10.3390/life14060747
APA StyleHu, T., Wang, L., Autelli, R., & Long, M. (2024). Bridging Discoveries and Treatments: The New Landscape of Breast Cancer Research. Life, 14(6), 747. https://doi.org/10.3390/life14060747